The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the launch of a Phase I/IIa trial of DemeRx and atai Life Sciences’ ibogaine HCl (DMX-1002) for the treatment of opioid use disorder (OUD).
MAC are excited to be collaborating with DemeRx on their phase 1 trial of Opioid Use Disorder. This clinical trial will be conducted at our MHRA accredited Early Phase Unit in Greater Manchester.
Deborah C Mash PhD, CEO and Founder of DemeRX thanked their strategic consultants and collaborators for their dedication and hard work needed to advance the drug development of Ibogaine. Stating “Together, we will help patients to break free from their intractable cycle of opioid dependence.”
